Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019–2024 - Scorecard - MDSpire
Advertisement
Patterns of Treatment and Outcomes for Patients Diagnosed with Metastatic Pancreatic Adenocarcinoma in the United States, 2019–2024
Clinical Scorecard: Patterns of Treatment and Outcomes for Patients Diagnosed with Metastatic Pancreatic Adenocarcinoma in the United States, 2019–2024
At a Glance
Category
Detail
Condition
Metastatic Pancreatic Adenocarcinoma
Key Mechanisms
Treatment patterns and survival outcomes associated with first-line regimens.
Target Population
US adults newly diagnosed with metastatic pancreatic adenocarcinoma.
Care Setting
Real-world clinical practice
Key Highlights
Approximately 50% of patients present with metastatic disease at diagnosis.
FOLFIRINOX associated with longer overall survival compared to Gem-Nab.
33.5% of patients did not receive systemic therapy within 180 days of diagnosis.
Mean time to first-line treatment initiation was 26.9 days.
Clinical and sociodemographic factors influenced treatment regimen selection.
Guideline-Based Recommendations
Diagnosis
Diagnosis of metastatic pancreatic adenocarcinoma is confirmed through imaging and histological evaluation.
Management
First-line regimens include FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Monitoring & Follow-up
Overall survival and time-to-treatment discontinuation should be assessed.
Risks
High mortality rate with 5-year survival at ~3% for metastatic pancreatic cancer.
Patient & Prescribing Data
Patients diagnosed with metastatic pancreatic adenocarcinoma in the US.
FOLFIRINOX is preferred in younger patients with better performance status.
Clinical Best Practices
Consider patient demographics and performance status when selecting treatment regimens.
Address barriers to timely initiation of systemic therapy.
